1-8 of 8
David Macdonald, MD FRCPC
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Results of the Primary Analysis of Complement A+B: A Phase III Study of Ofatumumab in Combination with Bendamustine Versus Bendamustine Alone in Patients with Indolent Non-Hodgkin's Lymphoma That Is Unresponsive Following Rituximab or Rituximab-Containing Regimen

Mathias J Rummel, MD PhD, Ann Janssens, David MacDonald, MD FRCPC, Mary-Margaret Keating, MD, Jan Zaucha, MD, Jaclyn Davis, MD, Janet Lasher, Nathalie Lobe, Miguel Izquierdo, Jonathan W. Friedberg, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 450.
https://doi.org/10.1182/blood-2018-99-114484
Published: 2018
Journal Articles

A Randomized, Phase II Study with Biomarker Analysis of Panobinostat with or without Rituximab in Relapsed Diffuse Large B Cell Lymphoma

Sarit Assouline, Michael Crump, MD, Torsten Holm Nielsen, Miguel Alcaide, B. Sc., Ph. D., David Macdonald, MD FRCPC, Axel Tosikyan, Tina Haliotis, Celia Greenwood, Kathleen Klein Oros, Ryan Morin, PhD, Nathalie Johnson, MD PhD, Koren Kathleen Mann, PhD
Journal: Blood
Blood (2015) 126 (23): 2719.
https://doi.org/10.1182/blood.V126.23.2719.2719
Published: 2015
Journal Articles

Pharmacokinetics (PK), Safety and Overall Response Rate (ORR) Achieved with Subcutaneous (SC) Administration of Rituximab in Combination with Chemotherapy Were Comparable to Those Achieved with Intravenous (IV) Administration in Patients (pts) with Follicular Lymphoma (FL) in the First-Line Setting: Stage 1 Results of the Phase III SABRINA Study (BO22334)

Andrew Davies, MD, Francesco Merli, Biljana Mihaljevik, Noppadol Siritanaratkul, MD, Philippe Solal-Céligny, MD, Axel Boehnke, Claude Berge, Christine McIntyre, Martin Barrett, PhD, David Macdonald, MD, FRCPC
Journal: Blood
Blood (2012) 120 (21): 1629.
https://doi.org/10.1182/blood.V120.21.1629.1629
Published: 2012
Journal Articles

Differences in Quality of Life Between Bendamustine Plus Rituximab Compared with Standard First-Line Treatments in Patients with Previously Untreated Advanced Indolent Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma

John M. Burke, MD, Richard H. Van der Jagt, MD, Brad S. Kahl, M.D., Peter Wood, MRCP, Tim E. Hawkins, MBChB, David MacDonald, MD, FRCPC, Mark Hertzberg, MBBS, PhD, Yiu-Lam Kwan, MBBS, David Simpson, MBChB, Michael Craig, MD, Kathryn Kolibaba, MD, Samar Issa, MBChB, FRACP, FRCPA, Richard E. White, PhD, MPH, MBE, Mihaela C. Munteanu, MS, Regina Clementi, RN, MS, Ling Chen, PhD, Ian W. Flinn, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 155.
https://doi.org/10.1182/blood.V120.21.155.155
Published: 2012
Journal Articles

An Open-Label, Randomized Study of Bendamustine and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in First-Line Treatment of Patients with Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL): The Bright Study

Ian W. Flinn, MD, PhD, Richard H. Van der Jagt, MD, Brad S. Kahl, M.D., Peter Wood, MRCP, Tim E. Hawkins, MBChB, David MacDonald, MD, FRCPC, Mark Hertzberg, MBBS, PhD, Yiu-Lam Kwan, MBBS, David Simpson, MBChB, Michael Craig, MD, Kathryn Kolibaba, MD, Samar Issa, MBChB, FRACP, FRCPA, Mihaela C. Munteanu, MS, Regina Clementi, RN, MS, Ling Chen, PhD, John M. Burke, MD
Journal: Blood
Blood (2012) 120 (21): 902.
https://doi.org/10.1182/blood.V120.21.902.902
Published: 2012
Journal Articles

Gemcitabine, Dexamethasone, Cisplatin (GDP) Compared to Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Prior to Autologous Stem Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: Final Results of the Randomized Phase III NCIC CTG Study LY12

Michael Crump, MD, FRCPC, John Kuruvilla, MD, FRCPC, Stephen Couban, MD, FRCPC, David Macdonald, MD, FRCPC, Vishal Kukreti, MD, C. Tom Kouroukis, MD, MSc, FRCPC, Ralph M. Meyer, MD, Morel Rubinger, MD, Rena Buckstein, MD, Kevin R Imrie, MD, Massimo Federico, MD, Nicola Di Renzo, MD, Kang Howson-Jan, MD, Tara Baetz, MD, Leonard Kaizer, MD FRCPC, Michael Voralia, MD, FRCPC, Harold J. Olney, MD, A. Robert Turner, MD, FRCPC, Jonathan Sussman, MD, Annette E Hay, MBChB, Marina Djurfeldt, MSc, Bingshu E Chen, PhD, Lois Shepherd, MD
Journal: Blood
Blood (2012) 120 (21): 745.
https://doi.org/10.1182/blood.V120.21.745.745
Published: 2012
Journal Articles

CPOP-R Versus CHOP-R As First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): A Phase 2, Randomized, Open-Label, Multicenter Study

Raoul Herbrecht, David MacDonald, MD, FRCPC, Florian Weissinger, MD, Martin Wilhelm, MD, Charles Holladay, MS, MD, Nam H. Dang, MD, PhD, Peter Holman, MD, Paul Cernohous, MS, Jack Singer, MD, Richard H. van der Jagt, MD, FRCPC
Journal: Blood
Blood (2011) 118 (21): 1605.
https://doi.org/10.1182/blood.V118.21.1605.1605
Published: 2011
Journal Articles

A Phase 2, Double-Blind, Placebo-Controlled Trial of Rituximab + Galiximab Vs Rituximab + Placebo In Advanced Follicular Non-Hodgkin's Lymphoma (NHL)

Isabelle Bence-Bruckler, MD, FRCPC, David Macdonald, MD, FRCPC, Patrick J Stiff, MD, Byron McKinney, MS, Katherine L. Ruffner, MD, Lynn Wilson, Margaret Whiteley, BSc, Brad Kahl, MD
Journal: Blood
Blood (2010) 116 (21): 428.
https://doi.org/10.1182/blood.V116.21.428.428
Published: 2010